Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02544633
Title Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Mirati Therapeutics Inc.
Indications

lung non-small cell carcinoma

Therapies

Glesatinib

Age Groups: adult
Covered Countries USA | ITA | CAN

Additional content available in CKB BOOST